Brexanolone Patent Expiration
Brexanolone is Used for treating postpartum depression. It was first introduced by Sage Therapeutics Inc
Brexanolone Patents
Given below is the list of patents protecting Brexanolone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zulresso | US10940156 | Neuroactive steroids, compositions, and uses thereof | Mar 08, 2037 | Sage Therap |
| Zulresso | US10251894 | Anticonvulsant activity of steroids | Nov 27, 2033 | Sage Therap |
| Zulresso | US10322139 | Neuroactive steroid formulations and methods of treating CNS disorders | Jan 23, 2033 | Sage Therap |
| Zulresso | US10117951 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Sage Therap |
| Zulresso | US7635773 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Sage Therap |
| Zulresso | US8410077 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Sage Therap |
| Zulresso | US9200088 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Sage Therap |
| Zulresso | US9750822 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Sage Therap |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brexanolone's patents.
Latest Legal Activities on Brexanolone's Patents
Given below is the list recent legal activities going on the following patents of Brexanolone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Nov, 2022 | US10322139 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Sep, 2022 | US10251894 |
| Patent Issue Date Used in PTA Calculation Critical | 09 Mar, 2021 | US10940156 |
| Recordation of Patent Grant Mailed Critical | 09 Mar, 2021 | US10940156 |
| Email Notification Critical | 18 Feb, 2021 | US10940156 |
| Issue Notification Mailed Critical | 17 Feb, 2021 | US10940156 |
| Dispatch to FDC | 29 Jan, 2021 | US10940156 |
| Email Notification Critical | 18 Jan, 2021 | US10940156 |
| Mail Response to 312 Amendment (PTO-271) Critical | 18 Jan, 2021 | US10940156 |
| Response to Amendment under Rule 312 Critical | 13 Jan, 2021 | US10940156 |
Brexanolone's Family Patents
